{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"236"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"236"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"64"},{"groupId":"OG003","value":"153"}]}],"title":"No"}],"denoms":[{"counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"393"},{"groupId":"OG002","value":"153"},{"groupId":"OG003","value":"389"}],"units":"Participants"}],"description":"Number (%) of participants with a Best Objective Response (BoR) of CR, PR, or SD. Complete response (ie., CR) was defined as disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \\<10 mm. Partial response (ie., PR) was defined as at least a 30% decrease in the sum of the diameter of TL, taking as reference the baseline sum of diameters. Stable disease (ie., SD) was defined as neither sufficient decrease in sum of diameters to qualify for PR nor sufficient increase to qualify for progression.","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS included all participants who were randomized. T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until objective tumor progression or date of death, assessed until the final analysis DCO (27Aug2021, to a maximum of approximately 46 months).","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Participants"}